Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474392 | 1.00 | ALDH1A1 (0.73) | ALDH1A1MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL21926849 | 0.91 | ALDH1A1 (0.67) | ALDH1A1MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL5474311 | 0.84 | HSD11B1 (0.68) | ALDH1A1KMT2AKDM4ERAB9AMEN1 | |
| SCHEMBL5474315 | 0.84 | HSD11B1 (0.68) | ALDH1A1KMT2AKDM4ERAB9AMEN1 | |
| SCHEMBL21928849 | 0.82 | HSD11B1 (0.71) | ALDH1A1KMT2ARAB9AMEN1LMNA | |
| SCHEMBL2636628 | 0.81 | ALDH1A1 (0.70) | ALDH1A1MAPTKMT2AKDM4ERAB9A | |
| SCHEMBL5480130 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2ARAB9AMEN1 | |
| SCHEMBL5480132 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2ARAB9AMEN1 | |
| SCHEMBL5479819 | 0.78 | HSD11B1 (0.60) | ALDH1A1KDM4ERAB9ALMNASMN1; SMN2 | |
| SCHEMBL5475256 | 0.78 | HSD11B1 (0.74) | ALDH1A1MAPTKMT2ARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 68/4885MAPT 4016/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.